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Abstract
The prevalence of Parkinson’s disease (PD) increases with age. Up to 50% of PD show cognitive decline in terms of a mild
cognitive impairment already in early stages that predict the development of dementia, which can occur in up to 80% of PD
patients over the long term, called Parkinson’s disease dementia (PDD). So far, diagnosis of PD/PDD is made according to
clinical and neuropsychological examinations while laboratory data is only used for exclusion of other diseases. The aim of
this study was the identification of possible biomarkers in cerebrospinal fluid (CSF) of PD, PDD and controls (CON) which
predict the development of dementia in PD. For this, a proteomic approach optimized for CSF was performed using 18
clinically well characterized patients in a first step with subsequent validation using 84 patients. Here, we detected
differentially sialylated isoforms of Serpin A1 as marker for differentiation of PD versus PDD in CSF. Performing 2D-
immunoblots, all PDD patients could be identified correctly (sensitivity 100%). Ten out of 24 PD patients showed Serpin A1
isoforms in a similar pattern like PDD, indicating a specificity of 58% for the test-procedure. In control samples, no additional
isoform was detected. On the basis of these results, we conclude that differentially sialylated products of Serpin A1 are an
interesting biomarker to indicate the development of a dementia during the course of PD.
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Introduction
An increasing prevalence for Parkinson’s disease (PD) can be
detected in advanced age, with 1% among 60-year-olds and 3% in
the 80-year-old age-group [1]. Of note is that patients with PD
have a roughly 6-times higher risk to develop a dementia than an
age-matched healthy control group [2]. Up to 50% of PD show
cognitive decline in terms of a mild cognitive impairment already
in early stages that predicts the development of dementia, which
can occur in up to 80% of PD patients over the long term [3,4].
The dementia syndrome usually develops after approximately 8 to
10 years and has a strong influence not only on the course of the
disease but also on the social environment with higher require-
ments for families and caretakers during everyday life. The latter
causes a psychological strain for the patient and family [5], leading
to increased stress during home care [6] with growing need for
professional care. The dementia syndrome is also accompanied
with a worse prognosis as regards disease-progression and life
expectancy [7]. Early treatment is critical for the modification of
the disease progress as acetylcholine esterase inhibitors have only a
delaying effect on worsening of cognitive deficits in early stages
when neurodegeneration is not exessively advanced. [8]. There-
fore, there is a clear need for a biomarker to define patients at risk.
Neuropathologically, PDD is characterized by cortical Lewy
bodies that also occur in patients with dementia with Lewy bodies.
However it is heretofore unclear whether both diseases are a
matter of a single one. By definition, diagnosis of PDD is made
when the onset of dementia is more than one year after the onset
of Parkinsonism whereas DLB should be diagnosed when
dementia occurs before or concurrently with Parkinsonism
[9,10,11,12,13]. As a rule both PDD and DLB are associated
with histological changes of Alzheimer’s disease [14]. It has been
shown that Lewy bodies contain alpha-synuclein, a presynaptic
filament protein that mainly is expressed in the terminal endings of
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neurons. Therefore, an obvious working theory is that these Lewy
bodies are directly linked to the pathophysiological processes,
especially that alpha-synuclein inclusions are mostly present in
surviving cells and less so in apoptotic cells, suggesting that these
inclusions may play a protective role in cell death by sequestering
toxic molecular species [15,16]. Regarding the formation of alpha-
synuclein containing inclusion bodies and their importance in
neuropathological alterations, Braak et al. were able to indicate a
topographical extent of these lesions with an initial onset in the
dorsal IX/X-motor nucleus and the intermediate reticular zone in
the brain stem, proceeding with an ascending course to cortical
structures, beginning with the anteromedial temporal mesocortex
[17,18,19]. As a possible link between neurotoxicity, aggregation
and propagation it might be concluded that species of neurotoxic
oligomers can be transformed to oligomers which are not
neurotoxic, but have a higher tendency of further aggregation
[20,21].
We and others made attempts to improve the early diagnosis of
dementia in PD patients by measurement of alpha-synuclein or
proposed alpha-synuclein aggregates and by known biomarkers in
CSF and serum [22,23,24,25]. However, for prognosis of disease
progression in an individual patient this neurochemical profile is
currently of limited use [22].
Using an optimized protocol for the proteomic analysis of CSF,
which particularly accounts for the brain protein variation caused
by CSF flow [26], we investigated a set of well defined clinical
groups of patients with PD, PDD and a control group to find a
marker which can differentiate between the demented and non-
demented persons. Thereby, we found that PDD patients can be
identified on the basis of differentially sialylated isoforms of Serpin
A1 in CSF. In a second step, this protein was validated in an
independent set of patients and investigated in human brain
material.
Results
PDD Patients can be Identified on the Basis of Serpin A1
Isoforms
In the first step of our study, identification of regulated proteins
relevant for differentiation of PD versus PDD was approached by
means of 2D-DIGE experiments. CSF samples of 6 patients per
group (PD, PDD, CON) were analysed, whereby an internal
standard consisting of a mixture of all 18 samples was used to
ensure the comparability of the gels during the subsequent
software-based evaluation. No pooling was performed, but two
samples from patients of different groups were loaded on a gel
together with the internal standard so that 18 gels were analysed in
total. Also a dye-switch was made to exclude false results due to
preferential binding of proteins to one dye. A representative gel is
shown in Figure 1. Relevant proteins were identified using
MALDI-ToF MS/MS analysis. Characteristics of all patients are
given in Table 1; Spot data for the identified proteins are shown in
Table 2.
In a second step, we examined the reproducibility of the 2D-
DIGE-data using 1D-immunoblotting as complementary ap-
proach. In order to maintain comparability with the proteomic
2D-DIGE, samples were also used volume-normalized. After
quantitative analysis of the protein-bands, Serpin A1 showed a
statistically significant regulation between PDD on one side and
PD/CON on the other (Figure 2A) with large overlap between the
analysed groups (Figure 3A/B).
On the basis of the pixel volumes out of the DIGE experiments,
we had expected a more prominent difference of Serpin A1
regulation in the subsequent validation phase as seen in our 1D-
immunoblot data. As the most likely explanation for this
discrepancy was that the Serpin A1 regulation seen in 2D-DIGE
was related to particular isoforms (which are not separated in the
conventional 1D-immunoblotting method), we performed 2D-
immunoblots to test for the presence of differential Serpin A1
isoforms in the groups. Here indeed, a different isoform-pattern
was detected with usually#5 spots in PD and CON and 6 or more
spots in PDD. Spots indicated as spot 1 and spot 2 are additionally
seen in PDD patients (Figure 3C). These results could also be
reproduced in the CSF-samples from Kuopio/Finland and
Perugia/Italy, which were investigated in a blinded manner to
test reproducibility of our data and to exclude a centre effect
caused by preanalytical handling procedures of CSF-samples.
In a next step, we were interested in the sensitivity and
specificity of Serpin A1 regarding its relevance as a possible
diagnostic marker to differentiate between PD and PDD. For this,
we analysed the cut-off of 5.5 spots obtained by ROC analysis and
also iterative testing. Using this cut-off (or $6 spots), we compared
PD and PDD and found a specificity of 58% and a sensitivity of
100% by 2D immunoblot approach. In the relevant diagnostic PD
group the additional spots were seen in 10 out of 24 patients;
interestingly, two patients who presented with more than 6 spots
developed a dementia in the course of disease (one patient
developed dementia already after one year whereas the other one
remained stable over a longer time). To test specificity among
dementia subgroups, a small set of patients with other dementia
like Alzheimer’s disease (AD) and fronto-temporal lobar degener-
ation (FTLD) were analyzed whereby the specificity in the
subgroups ranged from 71% in AD to 33% in the FTLD group
using the same cut-off of $6 spots. If more than 6 spots would be
used as a cut-off, than we would obtain a higher specificity with a
loss of sensitivity.
Posttranslational Modifications of the Serpin A1 Isoforms
To further characterize the additional Serpin A1 spots, a mass-
spectrometric analysis of the isoforms detected in the immunoblots
was done by LC-MS/MS using a LTQ Orbitrap XL mass-
spectrometer. Here, Serpin A1 was detected in all 7 spots from a
representative gel of a PDD-patient being the dominant protein in
spots 1 through 5 (Figure 2B). Serpin A1 was also detected in spots
6 and 7 but the dominant protein was identified as GC-vitamin D-
binding protein precursor.
The analysis of posttranslational modifications with emphasis on
possible glycosylations and phosphorylations was performed for
the Serpin A1 isoforms. While we failed to identify phosphoryla-
tions in any of the Serpin A1-spots, glycosylations were detected
for spots 3 to 7 but not for spots 1 and 2 (Table 3) which are the
diagnostic relevant ones to differentiate between PD and PDD. As
this does not necessarily mean that there are no glycosylations in
those spots, a PNGase F digest was performed which revealed that
all Serpin A1 spots in a PDD-patient harbour N-glycosylations
(Figure S1). However, as the additional Serpin A1 spots are still
present after PNGase F treatment, N-linked glycans (or more
precisely their terminal sialic acids) cannot be responsible for the
altered charge states. We therefore hypothesized that sialylated O-
linked glycans may be the underlying posttranslational modifica-
tions for the characteristic Serpin A1 spot pattern and tested this
hypothesis by performing a neuraminidase-digest. Indeed, we
found a shift of the Serpin A1 isoforms towards a more basic pI
(Figure 4). Most importantly, the diagnostic relevant acidic spots
disappeared, indicating a hypersialylation of those isoforms. This
hypersialylation is not due to a decrease in activity of neuramin-
idase (the enzyme responsible for desialylation), as this was found
to be unchanged in CSF (data not shown).
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Source of Additional Serpin A1 is the Brain
We analyzed Serpin A1 expression in brain tissues to investigate
whether the CSF protein amounts can be traced back to protein
release from the brain tissue into the CSF. As our patients show no
elevation of the age-dependent elevated Q-Alb (representation of
the blood-CSF barrier function), flow from the blood into the CSF
as source of our results is not likely. Nevertheless, we can not rule
out, that the Serpin A1 amount in the CSF has its source in the
choroid plexus with consecutive release into the CSF. 1D- and 2D-
immunoblot analysis revealed Serpin A1 expression in brain
material from both CON and patients with Lewy body dementia
which represent a pathologic pendant for PDD (Figure 5A).
However, the additional isoforms of Serpin A1 were not restriced
to patients with DLB and can also be identified in CON
(Figure 5B).
To investigate if the additional Serpin A1 spots were a direct
result of cell destruction in the brain, we correlated tau-values
above 450 pg/ml and the number of Serpin A1 spots $6
performing Spearman-rank correlations. No significant correlation
was found in the various subgroups (PD: r =20.102, p = 0.663;
PDD: r = 0.428, p= 0.0584; AD: r = 0.169, p = 0.662; FTLD:
r = 0.0, p = 1.0), so that we suppose that the Serpin A1 isoform-
distribution is a tau-level independent marker for PDD. We
intentionally did not investigate or compare values of amyloid ß 1–
42 because of the decreased stability of the protein. Our intention
was to avoid the preanalytical bias of false Aß 1–42 measurement
when comparing our samples to those from Perugia or Kuopio.
Discussion
Parkinson’s disease dementia is diagnosed according to clinical
criteria and neuropsychological examinations [27,28]. Since the
typical Parkinson motor-symptoms are initially predominant, the
cognitive impairments or even a dementia is often neglected and
detected in advanced stages [29]. In order to identify PD patients
who are at risk to develop a dementia, a laboratory biomarker
would be of great advantage.
In this study, CSF-analysis of patients with PD and PDD was
performed using proteomic methods in order to detect proteins of
potential diagnostic value. Of the six proteins identified, only the
serine-protease-inhibitor Serpin A1 could be verified with
biochemical methods to be statistically significant regulated – a
protein that was already described to be relevant in AD and DLB
[30]. However in the validation phase, there was a large overlap
Figure 1. Representative 2D-DIGE gel of CyDye-labeled CSF-proteins. Indication is given in black-white manner for better visibility. Arrows
indicate identified protein spots: number 1 for Serpin A1, number 2 for Fetuin A, number 3 for Ceruloplasmin, number 4 for Serpin F1, number 5 for
Haptoglobin and number 6 for Zinc-alpha-2 glycoprotein (numbers correlate with the numbers in the first row of Table 2). The magnification shows
spot number 1 in CyDye overlay. Abbreviations: pI = isoelectric point of the proteins; MW = molecular weight in kilo-Dalton.
doi:10.1371/journal.pone.0048783.g001
Table 1. Relevant parameters of all groups investigated.
Disease N m/f Age Tau (pg/ml) MMST Hoehn&Yahr
PD 24 9/15 6669 2646140 2664 2.161.1
PDD 21 10/11 7668 3266250 2066 2.961.1
AD 9 5/4 70613 7866427 2364 –
FTLD 6 4/2 6467 4506387 2762 –
CON 24 9/15 70606 – – –
Data are indicated as mean6SD.
Abbreviations: PD = Parkinson’s disease, PDD = Parkinson’s dementia, AD =
Alzheimer’s disease, FTLD = frontotemporal lobar degeneration, CON =
control persons, m/f = male/female, MMST = minimal mental status test.
doi:10.1371/journal.pone.0048783.t001
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among the different groups investigated so that according to those
experiments the total level of Serpin A1 can not be used as a
diagnostic marker. Therefore, we characterized the isoform-
distribution of Serpin A1 and identified a different protein-pattern
with 6 or more spots in PDD and with 5 spots or less in PD and
CON where spots 1 and/or 2 were indicative for differentiation of
PDD with 100% sensitivity and 58% specificity. These results
could be verified in a larger patient-cohort of three different
specialized centers (Ulm/Germany, Perugia/Italy and Kuopio/
Finland) whereby two PD cases with a 7/9 spot-pattern
interestingly developed a dementia in the course of their disease.
This may be suggestive that the isoform-pattern does not only help
to support the diagnosis but has also a predictive value, a
hypothesis that has to be followed up in further studies.
Although our principal goal was the identification of a
biomarker that differentiates PD patients from those with
additional dementia at the time of lumbar puncture in a cohort
with clinically and neuropsychologically proven diagnoses, we
additionally investigated the 2D spot pattern in other dementia
diseases to get the specificity of the protein among dementia-
subgroups. Here, patients with AD revealed in some cases
(specificity 71%) and in FTLD in more cases the typical spot
pattern (specificity 33%). Nevertheless, statistic based conclusions
can not be stated because of the small number of patients in the
subgroups and has to be reproduced with larger patient cohorts.
2D-immunoblotting is a sophisticated method and not applica-
ble for routine assessments, so that further analyses of posttrans-
lational modifications were performed and provided evidence for
glycosylation of the Serpin A1-isoforms. To investigate Serpin A1
glycosylation in more detail, we used the enzymes PNGase F to
remove N-linked glycans as well as neuraminidase to remove
terminal sialylation from N- and O-linked glycans. Only treatment
with the latter resulted in a shift of the Serpin A1 isoforms towards
a more basic pI and thereby in the disappearance of the two
relevant most acidic spots in PDD, indicating an O-linked
hypersialylation to be responsible for altered charged states of
those isoforms. However, this hypersialylation is obviously not
caused by an impaired neuraminidase function, as activity of this
enzyme does not change in the CSF of any of the groups analysed.
This may be the basis for future promising approaches to establish
a routine diagnostic assay for the diagnosis/differential diagnosis of
PD/PDD.
Since Serpin A1 belongs to the acute-phase proteins [31] in
plasma and it is known to be expressed in the liver and also in
macrophages [32], we had to confirm that Serpin A1 was indeed
brain derived. In a pilot experiment, human cortex samples of
patients with DLB and CON were analysed for Serpin A1
expression that could be investigated in brain tissue of both
diseased patients and CON without difference in the protein-spot
pattern. On the basis of these results, we supposed that the
additionally and hypersialylated isoforms in PDD are released into
the CSF, an assumption that is indirectly supported by the
previous finding that unglycosylated Serpin A1 or Serpin A1 with
reduced glycosylation is not secreted into the blood by hepatocytes
[33]. Assuming that this is also true for neurons, it would explain
why Serpin A1 can not differentiate between DLB and CON in
brain tissue. To rule out that the Serpin A1 isoforms are a
pathophysiological correlate of general cell destruction, we
performed correlation analyses with tau protein without differ-
ences of both proteins in our groups.
In general, glycosylation events have already been implicated in
the pathogenesis of neurodegenerative diseases [34,35,36]. How-
ever for PD and PDD, only little is known about the relevant
pathomechanisms of glycosylations and sialylations whereby a role
of alpha-synuclein glycosylation is discussed in the formation of
protein inclusions and disease progression [37,38]. Wang et al.
found that the phosphorylated alpha-synuclein is able to distin-
guish between PD and atypical parkinsonian syndroms like
multisystem atrophy or supranuclear palsy. This may indicate
that investigation of posttranslational modification of proteins is a
Table 2. 2D-DIGE analysis and identification of selected CSF proteins.
Spot
Protein
name Regulation Ratio
Swiss-Prot
accession
MW
[kDa] pI
PMF
coverage [%]
PMF
scorea)
Peptide
sequenced
MS/MS ion
scoreb)
1 Alpha-1-
antitrypsin
(Serpin A1)
PDD vs. CON
PDD vs. PD
1.61 1.80 P01009 46878 5.4 55 257 LYHSEAFTVNFGDTEEAK
LQHLENELTHDIITK
TDTSHHDQDHPTFNK
LYHSEAFTVNFGDTEEAKK
93
84
42
35
2 Alpha-2-HS
glycoprotein
(Fetuin A)
CON vs. PDD 21.32 P02765 40098 5.4 22 63 EHAVEGDCDFQLLK
HTFMGVVSLGSPSGEVSHP
HTFMGVVSLGSPSGEVSHPR
112
38
25
3 Ceruloplasmin PD vs. CON 22.23 P00450 122983 5.4 23 122 GAYPLSIEPIGVR
DLYSGLIGPLIVCR
46
33
4 Pigment
epithelium-
derived factor
(Serpin F1)
PDD vs. CON 1.59 P36955 46484 6.0 42 144 TSLEDFYLDEER
LAAAVSNFGYDLYR
38
25
5 Haptoglobin PDD vs. CON 1.75 P00738 45861 6.1 35 115 YVMLPVADQDQCIR
VGYVSGWGR
58
36
6 Zinc-alpha-2
glycoprotein
CON vs. PDD 21.79 P25311 34079 5.5 54 214 AREDIFMETLK
AYLEEECPATLR
YSLTYIYTGLSK
54
Abbreviations: PD = Parkinson’ disease, PDD = Parkinson’s dementia, CON = control persons, pI = isoelectric point of the proteins, PMF = peptide mass fingerprint,
MS = mass spectrometry.
a) Mascot protein score obtained for the peptide mass fingerprint (PMF). The significance threshold was 56.
b) Mascot MS/MS ion scores obtained for the individual peptides sequenced. The significance threshold was 17–29 depending on how many peptides fell within the
mass tolerance window about the precursor mass. Only the top ranking peptides matching a query for the first time (‘‘bold red hits’’) are reported.
doi:10.1371/journal.pone.0048783.t002
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better marker to distinguish diseases than the proteins itsself [39].
Analogous to AD, Huntington disease and CJD [40], an
accumulation of pathological aggregates through serine-protease-
inhibitors – in addition to the role of alpha-synuclein in the
pathogenesis of the disease [41,42,43] - can be assumed and PDD
could therefore be a subgroup of neurodegenerative diseases with
cerebral protein aggregation.
Interestingly, Serpin A1 is not only involved in folding of other
proteins but also is, like tau protein and amyloid-beta peptides,
able to polymerise and form aggregates itself [44,45,46]. Those
aggregates were investigated in some diseases with liver-cirrhosis
where Serpin A1-aggregation can be detected in liver tissue [45].
Additionally, those aggregations were found to be relevant in the
development of a dementia syndrome caused by autosomal-
dominant familiar encephalopathy with neuroserpin inclusion
bodies, indicating that both diseases may belong to the common
disease entity of serpinopathies [45,47,48]. One could hypothesize
that the formation of Serpin A1 aggregates takes place in PDD,
possibly triggered by differences in posttranslational modifications
– (hyper-)sialylation instead of phosphorylation – leading to a
different structure and (mal-)function of the protein so that the
formation of aggregates is favoured. In order to refute or confirm
this theory, further investigations especially pathophysiological-,
histological- and animal-based ones are necessary. Here, a
comprehensive amount of patients should be investigated.
Independent of these pathophysiological hypotheses, we sup-
pose that the hypersialylated isoforms of Serpin A1 have a
predictive value for the development of dementia in PD patients
which is worth to be followed up.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The local ethics committees (Ethik-
Kommission der Medizinischen Fakulta¨t der Universita¨t Ulm,
approval numbers: 8801 and 100305 and the regional Ethical
Committee Board (CEAS) of the University of Perugia, protocol
number 19369/08/AV as well as the Ethics Committee of Kuopio
University Hospital, number 5/2002) approved all experiments
within our study. All patients provided written informed consent
for the collection of samples and subsequent analysis. In case of
severe demented patients, their relatives gave written informed
consent to their participation in the study. The capacitiy of the
patients to consent was assessed by means of clinical, neurological
and neuroradiological examinations as well as a neuropsycholog-
ical screening to investigate global cognitive functions. All PD and
PDD patients underwent a detailed psychometric test battery (in
detail described in [26]), covering the following tests: MMSE,
Geriatric Depression scale, Parkinson Neuropsychometric De-
mentia Assessment, Regensburger Wortfluessigkeitstest (RWT),
Doors Test, Alertness/Go/NoGo/geteilte Aufmerkamkeit, Boston
Naming Test, Wechsler Memory Scale (WMS-R), Melmstaedter,
Coloured Progressive Marices, VOSP, Clock Test.
Patients
All CSF samples used for the proteomic approach were taken
from patients attending the general outpatient clinic (University of
Ulm, Department of Neurology) in 2006/2007. CSF was stored at
Figure 2. Identification and regulation of Serpin A1 and its different isoforms. 2A illustrates the 2D-DIGE analysis with the pixel volume
distribution for Serpin A1 corresponding to number 2 in Figure 1. The horizontal lines indicate the median value. Average ratios CON vs PDD 2.34,
PDD vs PD 1.80. p-values CON vs PDD 0.014, PDD vs PD 0.043. 2B shows the isoform distribution of Serpin A1 of a representative PDD gel with
spectral counts for the respective isoforms.
doi:10.1371/journal.pone.0048783.g002
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280uC after analysis of the routine parameters cell count, lactate,
Q-albumin and total protein until further analysis. For the
validation study, additional samples were obtained in blinded
manner from two different centers: Department of Neurology,
Kuopio, Finland (9 PD, 7 PDD) and Department of Neurology,
Perugia, Italy (8 PD, 8 PDD).
All individuals underwent a clinical, neurological, neuroradio-
logical examination and a short neuropsychological screening to
investigate global cognitive functioning. Patients were examined
neuropsychologically for unambiguous classification of their
mental status and exclusion of depressive syndroms. All PD and
PDD patients in Ulm were investigated with a detailed psycho-
metric test battery, described in [28].
Patients with PD, PDD and other Dementia (AD and
FTLD)
The number of patients per group, tau protein values, and the
minimental status test (MMST) for all groups and Hoehn&Yahr
stages for PD and PDD are indicated in Table 1. Tau protein was
measured in each clinical center.
The diagnosis of all PD/PDD patients was made in accordance
with the consensus criteria for PD/PDD [13] as well as on the
basis of the DSM-IV criteria and was established by neurologists
and neuro-psychologists, both blinded with regard to the
neurochemical outcome measures. Patients with PD were on
medication with L-dopa agonists or on L-dopa itsself; patients with
PDD were additionally treated with rivastigmine.
Figure 3. 1D- and 2D-immunoblots of Serpin A1. 3A shows 1D-immunoblot band volumes (adjusted for membrane background) of Serpin A1.
3B shows the statistical analysis for the 1D-immunoblot validation of all proteins found to be regulated in the 2D DIGE experiment. Only Serpin A1
displayed a significant regulation. 3C illustrates the 2D immunoblot of Serpin A1 with the different spot-pattern in PD/CON and PDD with the
relevant additional spots 1 and/or 2 in PDD. 3D shows the distribution of spot pattern in the different groups (PDD, PD versus the dementia
subgroups and CON). *Both PD-patients with 7/9 Serpin A1 spots developed dementia in the course of the disease. Abbreviations: PD = Parkinson’s
disease, PDD = Parkinson’s dementia, CON = control persons, AD = Alzheimer’s disease, FTLD = frontotemporal lobar degeneration, pI =
isoelectric point of the proteins.
doi:10.1371/journal.pone.0048783.g003
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Diagnosis of Alzheimer’s disease (AD) was set according to the
NINCDS-ADRDA criteria [49], the appropriate diagnosis of
FTLD-patients was done in accordance with the consensus criteria
for FTLD [50,51] as well as on the basis of the DSM-IV criteria.
Control Subjects (CON)
The control patients showed neither extrapyramidal-motor nor
dementia-specific symptoms. The final diagnoses of the patients
were as follows: vertigo (n = 2), paresthesia (n = 2), ischemia (n = 4),
complex focal seizures (n = 3), pseudotumor cerebri (n = 1), lumbo-
ischialgia (n = 3), migraine (n = 1), sharp-syndrom (n= 1), Tolosa
Hunt syndrom (n= 1), Arteriitis temporalis (n = 2), polyradiculo-
pathy (n = 1), transient global amnesia (n = 2) and dissociative
disorders (n = 1).
Neuropathology
Samples of human brain cortex tissues from 2 patients with
PDD/DLB (age of 63/80 years, tau-pathology of Braak stage II
and III, Lewy-bodies neocortically localized) and 2 CON (age of
59/46 years, tau-pathology of Braak stage 0 and I, no Lewy-
bodies) were obtained from the German Brain Bank (Ludwig-
Maximilians University, Munich). PDD is neuropathologically
characterized by cortical Lewy bodies that also occur in patients
with dementia with Lewy bodies. However it is heretofore unclear
whether both diseases are a matter of a single one.
CyDye Labeling
Proteomic analysis via 2D-DIGE was done with a volume-based
normalization as described previously [26] with the exception that
6 individual samples of each group were compared. In brief,
400 ml of each CSF sample were concentrated by VivaSpin
columns with a 3 kDa cut-off (Sartorius Biolabs products), then
albumin and immunglobuline were depleted. For conventional gel
staining, the depleted CSF was acetone-precipitated and resus-
pended in 7 M urea, 2 M thiourea, 4% CHAPS, 1% DTT, 1%
IPG Buffer (40%) pH 4–7 by rocking for 1 h at ambient
temperature. For CyDye labeling, precipitated proteins were lysed
in 7 M Urea, 2 M Thiourea, 4% CHAPS, 30 mM Tris-HCl
pH 8.1 at 10uC. Insoluble fractions were removed by centrifuga-
tion. For CSF proteome comparison in the first instance, 6
individual CSF samples of each group were compared by the
mixed internal standard methodology described by Alban et al.
[52]. CSF proteins were labeled with CyDyesTM (GE Healthcare),
fluorescent dyes developed for the difference gel electrophoresis-
system. Individual samples were labeled either with Cy3 or Cy5
for a dye-switched comparison to avoid potential dye-to-protein
preferences. For the mixed internal standard, aliquots of each
Table 3. Posttranslational modifications of Serpin A1.
spot # m/z (z)
neutral mass
(Da) glycan fragments observed
spot 1 – – None observed
spot 2 – – None observed
spot 3 906.4291 (+2) 1810.8436 (HexNAc)(Hex)(NeuAc)
spot 4 906.4286 (+2) 1810.8426 (HexNAc)(Hex)(NeuAc)
670.9987 (+3) 2009.9746 (HexNAc)(Hex)(NeuAc)
675.6698 (+3) 2023.9900 (HexNAc)(Hex)(NeuAc)
913.4363 (+2) 1824.8580 (HexNAc)(Hex)(NeuAc)
spot 5 906.4276 (+2) 1810.8406 (HexNAc)(Hex)(NeuAc)
675.6693 (+3) 2023.9861 (HexNAc)(Hex)(NeuAc)
670.9987 (+2) 2009.9743 (HexNAc)(Hex)(NeuAc)
913.4363 (+3) 1824.8580 (HexNAc)(Hex)(NeuAc)
1223.8602 (+3) 3668.5582 (HexNAc)2(Hex)2(NeuAc)2
1227.1494 (+3) 3678.4252 (HexNAc)2(Hex)2(NeuAc)2
1320.8926 (+3) 3959.6572 (HexNAc)2(Hex)2(NeuAc)2
spot 6 760.8801 (+2) 1519.7456 (HexNAc)(Hex)
778.8799 (+2) 1555.7452 (HexNAc)(Hex)
906.4281 (+2) 1810.8380 (HexNAc)(Hex)(NeuAc)
583.3101 (+3) 1746.9085 (HexNAc)(Hex)
1005.9940 (+2) 2009.9734 (HexNAc)(Hex)(NeuAc)
1013.0013 (+2) 2023.9884 (HexNAc)(Hex)(NeuAc)
1020.0094 (+2) 2038.0034 (HexNAc)(Hex)(NeuAc)
1133.5909 (+2) 2265.1674 (HexNAc)(Hex)(NeuAc)
spot 7 760.8811 (+2) 1519.7476 (HexNAc)(Hex)
860.4453 (+2) 1718.8784 (HexNAc)(Hex)
659.0319 (+3) 1974.0739 (HexNAc)(Hex)
906.4280 (+2) 1810.8414 (HexNAc)(Hex)(NeuAc)
913.4352 (+2) 1824.8562 (HexNAc)(Hex)(NeuAc)
1005.9948 (+2) 2009.9734 (HexNAc)(Hex)(NeuAc)
1013.0012 (+2) 2023.9874 (HexNAc)(Hex)(NeuAc)
1048.4598 (+4) 4189.8109 (HexNAc)2(Hex)2(NeuAc)2
1003.0392 (+5) 5010.1586 Indeterminate
Listing of glycosylation residues for Serpin A1 isoforms represented by spot 1 to
7 of a 2D DIGE experiment. Interestingly, spots number 1 and 2 seem not to be
glycosylated. Abbreviations: HexNAc = N-acetyl-hexosamine, Hex = hexose
(mannose, glucose or galactose), NeuAc = sialinic acid.
doi:10.1371/journal.pone.0048783.t003
Figure 4. Investigation of posttranslational modifications.
Immunoblot of Serpin A1 in a PDD-patient with and without
neuraminidase-treatment (different exposures of times are shown to
better visualize the individual spots, intensity of both blots were similar;
exposure time for the immunoblot without neuraminidase-treatment
= 2 seconds, exposure time for the immunoblot with neuraminidase-
treatment = 10 seconds). Treatment with the enzyme leads to an
isoform shift towards a more basic pI and thereby to the disappearance
of the diagnostic relevant most acidic spots 1 and/or 2. ‘‘Untreated’’
means usage of a native CSF-sample without neuraminidase-digest.
doi:10.1371/journal.pone.0048783.g004
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individual sample included in the experiment were pooled and
labeled with Cy2 in the same dye-to-CSF ratio. The labeling
reaction was stopped by 20 nmol lysine. The labeled samples were
combined and diluted 1.33 x by a stock solution containing 7 M
urea, 2 M thiourea, 4% CHAPS, 4% IPG-buffer pH 4–7, 4%
DTT w/v for subsequent IEF.
2D Gel Electrophoresis and Imaging
Isoelectric focusing was done as described previously [26].
Second dimension SDS-PAGE was performed with homogeneous
12.5% gels (2546200 mm) according to Tastet et al. [53] at
3.5 W/gel overnight at 20uC. The fluorescence signals of the 3
differently Cy-labeled protein samples were imaged using a laser
scanner (DIGE Imager, GE Healthcare) recording emission
wavelengths of 520 nm (Cy2), 580 nm (Cy3) and 670 nm (Cy5).
Proteins were post-stained with silver. Spots of interest were
excised manually and subjected to mass spectrometric protein
identification.
In-gel Digest, Mass Spectrometry and Database Search
Manually excised gel plugs were subjected to an automated
platform for the identification of gel-separated proteins [54] as
described in recent DIGE-based [26,55,56] and large-scale
proteome studies [56,57]. Briefly, a peptide mass fingerprint
(PMF) and six fragment ion spectra for each sample were recorded
automatically with an Ultraflex MALDI-ToF mass spectrometer
(Bruker Daltonics) under the control of the FlexControl 3.0
operation software. Post-processing of mass spectra and generation
Figure 5. Immunoblots of Serpin A1 in human cortex tissue. 5A shows 1D-immunoblot in two CON and two patients with Lewy body
dementia as a pathophysiological correlate of Parkinson’s dementia. The protein can be identified in both tissues of control persons and PDD
patients. 5B illustrates 2D-immunoblot for Serpin A1 of the patients investigated in 4A. The isoform pattern seen in CSF of CON/PD and PDD
(Figure 3C) with spot 1 and/or 2 indicative for PDD could not be reproduced in human cortex tissue. Abbreviations: CON = control persons, DLB =
Lewy body dementia, pI = isoelectric point of the proteins.
doi:10.1371/journal.pone.0048783.g005
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of peak lists was performed with the FlexAnalysis 3.0 software
(Bruker Daltonics).
PMF and MS/MS data sets were batch-processed using the
BioTools 3.1 software (Bruker Daltonics) as interface to the Mascot
2.2 software (Matrix Science) licensed in-house. Database searches
were performed in the Swiss-Prot primary sequence database,
restricted to the taxonomy homo sapiens. Carboxamidomethylation
of Cys was specified as fixed and oxidation of Met as variable
modification. One trypsin missed cleavage was allowed. Mass
tolerances were set to 100 ppm for PMF searches and to 100 ppm
(precursor ions) and 0.7 Da (fragment ions) for MS/MS ion
searches. The minimal requirement for accepting a protein as
identified was at least one peptide sequence match above identity
threshold in coincidence with at least 20% sequence coverage
assigned in the PMF.
Characterization of Serpin A1 Isoforms LC-MS/MS
Samples were subjected to proteolytic digestion on a ProGest
(Genomic Solutions) workstation as follows: Samples were reduced
with DTT at 60uC and then cooled to room temperature.
Furthermore, samples were alkylated with iodoacetamide and
subsequently incubated at 37uC for 4 h in the presence of trypsin.
Formic acid was added to stop the reaction and the supernatant
was analyzed directly by nano LC/MS/MS on a ThermoFisher
LTQ Orbitrap XL. 30 ml of hydrolysate was loaded onto a
5 mm675 mm ID C12 (Jupiter Proteo, Phenomenex) vented
column at a flow-rate of 10 mL/min. Gradient elution was over a
15 cm675 mm ID C12 column at 300 nL/min. A 30 min
gradient was employed. The mass spectrometer was operated in
data-dependent mode and the six most abundant ions were
selected for MS/MS. The Orbitrap MS scan was performed at
60,000 FWHM resolutions. MS/MS data were searched using a
local copy of Mascot (www.matrixscience.com). The parameters
for all LC/MS/MS searches were as follows: Type of search: MS/
MS ion search. Taxonomy: human. Enzyme: trypsin. Fixed
modifications: carbamidomethyl (C). Variable modifications:
oxidation (M), acetyl (N-term), pyro-glu (N-term Q), methyl
(various), deamidation (NQ), PO4 (STY). Mass values: mono-
isotopic. Protein mass: unrestricted. Peptide mass tolerance:
610 ppm (Orbitrap). Fragment mass tolerance: 60.5 Da (LTQ).
Maximum missed cleavages: 2.
Immunoblotting
Equal amounts of total protein or equal volumes (CSF) were
denatured and subjected to a SDS-PAGE in 12% polyacrylamide
gels. Proteins were transferred onto PVDF membranes (Millipore,
USA), correct transfer was checked by Ponceau Red S staining.
The membranes were incubated with the respective primary
antibody (see below) followed by incubation with HRP conjugated
secondary antibodies. Signal detection was performed by en-
hanced chemiluminescence (GE healthcare) on a CCD-camera.
For 2D-immunoblotting, strips were equilibrated for 2620 min in
6 M urea, 125 mM Tris-HCL pH 7.85, 3% SDS and 20%
glycerol (v/v). 1% dithiothreitol (DTT) and 4.2% iodoacetic acid
(IAA) were added for the first and second equilibration step,
respectively. The following primary antibodies were used:
Ceruloplasmin (BD-Biosciences 611488), Fetuin A (R&D Systems
BAF1184), Haptoglobin Hp2 (Abcam AB52652), Serpins A1, A8,
F1 (R&D Systems MAB1268, BAF3156, BAF 1177) and Zinc-
alpha-2 Glycoprotein (BD Biosciences 612354).
PNGase F and Neuraminidase Digests
In order to assess possible glycosylations or sialylations of the
serpin A1 isoforms, 5 ml of CSF was digested with PNGase F (New
England Biolabs) or neuraminidase (Roche, 1585886) as stated by
the manufacturers and subjected to a 2D-immunoblot.
Neuraminidase Assay
To quantitatively assess the neuraminidase level in CSF, a
commercially available Neuraminidase Assay kit (Molecular
probes) was used according to the manufacturer’s instructions.
CSF was measured in a 1+1 dilution.
Calculations and Statistics
Band volumes of immunoblots (adjusted for membrane
background) were determined using the Quantity One software
(BioRad).
Analysis for significant differences in a given parameter between
all tested groups or between two groups were calculated by
Kruskal-Wallis test or Mann-Whitney test. Correlation between
parameters was examined applying Spearman rank correlation. P-
values p#0.05 were considered to be significant. For ROC
analysis, p-values p#0.01 were considered significant (sigma plot
software 10.0). Standard measures of diagnostic test validity such
as sensitivity and specificity were calculated for the diagnostic
groups [58].
Supporting Information
Figure S1 Representative Serpin A1-blots of PNGase F-
treated CSF of PD and PDD. Abbreviations: PD=Parkinson’s
disease, PDD = Parkinson’s disease dementia
(TIF)
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